{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:21:42Z","timestamp":1772515302334,"version":"3.50.1"},"reference-count":140,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:00:00Z","timestamp":1559433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/QUI\/50006\/2019"],"award-info":[{"award-number":["UID\/QUI\/50006\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/BD\/113565\/2015"],"award-info":[{"award-number":["PD\/BD\/113565\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Marine Drugs"],"abstract":"<jats:p>The role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important breakthroughs associated with the use of marine-derived anticancer agents that have altered the current paradigm in chemotherapy. In addition, the discovery and development of marine drugs has been extremely rewarding with significant scientific gains, such as the discovery of new anticancer mechanisms of action as well as novel molecular targets. Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer.<\/jats:p>","DOI":"10.3390\/md17060329","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T02:08:40Z","timestamp":1559527720000},"page":"329","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-7364","authenticated-orcid":false,"given":"Renato B.","family":"Pereira","sequence":"first","affiliation":[{"name":"REQUIMTE\/LAQV, Laborat\u00f3rio de Farmacognosia, Departamento de Qu\u00edmica, Faculdade de Farm\u00e1cia, Universidade do Porto, R. Jorge Viterbo Ferreira, n\u00b0 228, 4050-313 Porto, Portugal"}]},{"given":"Nikolai M.","family":"Evdokimov","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106, USA"}]},{"given":"Florence","family":"Lefranc","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0740-4396","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Valent\u00e3o","sequence":"additional","affiliation":[{"name":"REQUIMTE\/LAQV, Laborat\u00f3rio de Farmacognosia, Departamento de Qu\u00edmica, Faculdade de Farm\u00e1cia, Universidade do Porto, R. Jorge Viterbo Ferreira, n\u00b0 228, 4050-313 Porto, Portugal"}]},{"given":"Alexander","family":"Kornienko","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-7592","authenticated-orcid":false,"given":"David M.","family":"Pereira","sequence":"additional","affiliation":[{"name":"REQUIMTE\/LAQV, Laborat\u00f3rio de Farmacognosia, Departamento de Qu\u00edmica, Faculdade de Farm\u00e1cia, Universidade do Porto, R. Jorge Viterbo Ferreira, n\u00b0 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9764-3920","authenticated-orcid":false,"given":"Paula B.","family":"Andrade","sequence":"additional","affiliation":[{"name":"REQUIMTE\/LAQV, Laborat\u00f3rio de Farmacognosia, Departamento de Qu\u00edmica, Faculdade de Farm\u00e1cia, Universidade do Porto, R. Jorge Viterbo Ferreira, n\u00b0 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8727-9678","authenticated-orcid":false,"given":"Nelson G. M.","family":"Gomes","sequence":"additional","affiliation":[{"name":"REQUIMTE\/LAQV, Laborat\u00f3rio de Farmacognosia, Departamento de Qu\u00edmica, Faculdade de Farm\u00e1cia, Universidade do Porto, R. Jorge Viterbo Ferreira, n\u00b0 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/jo01128a007","article-title":"Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. Spongothymidine and spongouridine","volume":"11","author":"Bergmann","year":"1955","journal-title":"J. Org. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1517\/17460441.2015.1059816","article-title":"Academic drug discovery: current status and prospects","volume":"10","author":"Everett","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1039\/C7NP00052A","article-title":"Marine natural products","volume":"35","author":"Blunt","year":"2018","journal-title":"Nat. Prod. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/md13010202","article-title":"Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012","volume":"13","author":"Hu","year":"2015","journal-title":"Mar. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/ci0200467","article-title":"Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry","volume":"43","author":"Feher","year":"2003","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jpba.2017.07.035","article-title":"Hybrid MS\/NMR methods on the prioritization of natural products: applications in drug discovery","volume":"147","author":"Gomes","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tips.2017.06.005","article-title":"Lessons learned from two decades of anticancer drugs","volume":"38","author":"Liu","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gomes, N.G.M., Dasari, R., Chandra, S., Kiss, R., and Kornienko, A. (2016). Marine invertebrate metabolites with anticancer activities: solutions to the \u201csupply problem\u201d. Mar. Drugs, 14.","DOI":"10.3390\/md14050098"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood.V21.3.352.352","article-title":"Megaloblastosis produced by a cytosine antagonist: 1-\u03b2-\u1d05-arabinofuranosylcytosine","volume":"21","author":"Talley","year":"1963","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.V18.4.431.431","article-title":"Studies of sequential and combination antimetabolite therapy in acute leukemia: 6\u2013mercaptopurine and methotrexate","volume":"18","author":"Frei","year":"1961","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/1097-0142(196803)21:3<341::AID-CNCR2820210302>3.0.CO;2-F","article-title":"Cytosine arabinoside: Results of a cooperative study in acute childhood leukemia","volume":"21","author":"Howard","year":"1968","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2012.10.005","article-title":"A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3","volume":"50","author":"Lichtman","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","article-title":"Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis","volume":"17","author":"Glantz","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_17","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained\u2013release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1015752331041","article-title":"An open label trial of sustained\u2013release cytarabine (DepoCytTM) for the intrathecal treatment of solid tumor neoplastic meningitis","volume":"57","author":"Jaeckle","year":"2002","journal-title":"J. Neurooncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ctrv.2015.12.004","article-title":"Therapy of leptomeningeal metastasis in solid tumors","volume":"43","author":"Mack","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_20","unstructured":"ClinicalTrials.gov (2019, March 15). Cytarabine, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=cytarabine&cntry=&state=&city=&dist=&Search=Search."},{"key":"ref_21","unstructured":"European Union Clinical Trials Register (2019, March 15). Cytarabine. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr\u2013search\/search?query=cytarabine."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1021\/jo00302a007","article-title":"Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumour agents from the Caribbean tunicate Ecteinascidia turbinata","volume":"55","author":"Rinerhart","year":"1990","journal-title":"J. Org. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/annonc\/mds659","article-title":"Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: Results of a worldwide expanded access program study","volume":"24","author":"Samuels","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2011.09.019","article-title":"A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study","volume":"124","author":"Monk","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2012.06.034","article-title":"Patient\u2013reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone","volume":"127","author":"Krasner","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdv071","article-title":"Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: Exploratory analysis of the phase 3 OVA-301 study","volume":"26","author":"Monk","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00280-007-0583-8","article-title":"Semimechanistic pharmacokinetic\/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment","volume":"62","author":"Fetterly","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins\u2014Antitumor polyether macrolides from a marine sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open\u2013label randomized study","volume":"377","author":"Loesch","year":"2011","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-11-3075","article-title":"The European Medicines Agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the Committee for Medicinal Products for Human Use","volume":"18","author":"Pean","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/14656566.2016.1146683","article-title":"Review on the clinical use of eribulin mesylate for the treatment of breast cancer","volume":"17","author":"Aseyev","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2125.2012.04381.x","article-title":"Pharmacokinetics of eribulin mesylate in patient with solid tumours receiving repeated oral rifampicin","volume":"75","author":"Devriese","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00498254.2010.542256","article-title":"Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P\u2013glycoprotein in CF\u20131 abcb1a\u2013deficient mice and Caco\u20132 cells","volume":"41","author":"Taur","year":"2011","journal-title":"Xenobiotica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-017-0466-3","article-title":"Emerging therapies for breast cancer","volume":"10","author":"Hu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"PD6-13","DOI":"10.1158\/1538-7445.SABCS17-PD6-13","article-title":"Phase 1b\/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple\u2013negative breast cancer","volume":"78","author":"Tolaney","year":"2018","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open\u2013label, multicentre, phase 3 trial","volume":"387","author":"Chawla","year":"2016","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"caC10\u2013vcMMAE, an anti\u2013CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN\u201335) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma","volume":"18","author":"McGinn","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1634\/theoncologist.2015-0276","article-title":"The European Medicines Agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use","volume":"21","author":"Gravanis","year":"2016","journal-title":"Oncologist"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1185\/03007995.2015.1048208","article-title":"Brentuximab vedotin compared with other therapies in relapsed\/refractory Hodgkin lymphoma post ASCT: Median overall survival meta-analysis","volume":"31","author":"Bonthapally","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood.V122.21.1809.1809","article-title":"Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"122","author":"Pro","year":"2013","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcph.116","article-title":"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies","volume":"53","author":"Han","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front\u2013line treatment of patients with CD30+ peripheral T\u2013cell lymphomas: Results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.hoc.2013.10.005","article-title":"Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma","volume":"28","author":"Younes","year":"2014","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentixumab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/17425255.2015.1007950","article-title":"Brentuximab vedotin for treating Hodgkin\u2019s lymphoma: An analysis of pharmacology and clinical efficacy","volume":"11","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1021\/np50070a001","article-title":"Bioactive compounds from aquatic and terrestrial sources","volume":"53","author":"Rinehart","year":"1990","journal-title":"J. Nat. Prod."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-07-1652","article-title":"Phase I clinical and pharmacokinetic study of plitidepsin as a 1\u2013hour weekly intravenous infusion in patients with advanced solid tumors","volume":"14","author":"Izquierdo","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/DDDT.S94165","article-title":"Plitidepsin: Design, development, and potential place in therapy","volume":"11","author":"Pardal","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-10-0469","article-title":"Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma","volume":"16","author":"Mateos","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_57","first-page":"1886","article-title":"Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed\/refractory multiple myeloma","volume":"130","author":"Spicka","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/annonc\/mdv195","article-title":"Aplidin in patients with advanced dedifferentiated liposarcomas: A French Sarcoma Group Single-Arm phase II study","volume":"26","author":"Toulmonde","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/md7010057","article-title":"Phase II randomized study of Plitidepsin (Aplidin), alone or in association with l-carnitine, in patients with unresectable advanced renal cell carcinoma","volume":"7","author":"Guillem","year":"2009","journal-title":"Mar. Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1517\/21678707.2013.808995","article-title":"Plitidepsin: An orphan drug","volume":"1","author":"Danu","year":"2013","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-13-1880","article-title":"First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors","volume":"20","author":"Elez","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdx111","article-title":"Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant\/refractory advanced ovarian cancer","volume":"28","author":"Poveda","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"TPS5597","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5597","article-title":"CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer","volume":"34","author":"Gaillard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"TPS8587","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8587","article-title":"ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small\u2013cell lung cancer after platinum therapy","volume":"36","author":"Farago","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.3390\/md13063950","article-title":"Can some marine\u2013derived fungal metabolites become actual anticancer agents?","volume":"13","author":"Gomes","year":"2015","journal-title":"Mar. Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.cad.0000182745.01612.8a","article-title":"NPI\u20132358 is a tubulin\u2013depolymerizing agent: In\u2013vitro evidence for activity as a tumor vascular\u2013disrupting agent","volume":"17","author":"Nicholson","year":"2006","journal-title":"Anticancer Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1182\/blood.V128.22.2508.2508","article-title":"Plinabulin, a novel small molecule that ameliorates chemotherapy-induced neutropenia, is administered on the same day of chemotherapy and has anticancer efficacy","volume":"128","author":"Blayney","year":"2016","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1158\/1078-0432.CCR-10-1096","article-title":"Phase 1 first\u2013in\u2013human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas","volume":"16","author":"Mita","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.2017.35.7_suppl.139","article-title":"Plinabulin as a novel small molecule clinical stage immune-oncology agent for NSCLC","volume":"35","author":"Mohanlal","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2018.36.5_suppl.126","article-title":"Plinabulin, a novel small molecule clinical stage IO agent with anti-cancer activity, to prevent chemo\u2013induced neutropenia and immune related AEs","volume":"36","author":"Mohanlal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_71","unstructured":"ClinicalTrials.gov (2019, March 17). Plinabulin, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=plinabulin&cntry=&state=&city=&dist=&Search=Search."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","article-title":"Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results","volume":"22","author":"Harrison","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/1871520614666141114202606","article-title":"Marizomib, a potent second generation proteasome inhibitor from natural origin","volume":"15","author":"Ma","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e14083","DOI":"10.1200\/JCO.2018.36.15_suppl.e14083","article-title":"A phase 1, multicenter, open\u2013label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): dose\u2013escalation results","volume":"36","author":"Bota","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1021\/cb400461j","article-title":"New interfacial microtubule inhibitors of marine origin, PM050489\/PM060184, with potent antitumor activity and a distinct mechanism","volume":"8","author":"Pera","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10164","DOI":"10.1021\/ja404578u","article-title":"Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds","volume":"135","author":"Coello","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Galmarini, C.M., Martin, M., Bouchet, B.P., Guillen-Navarro, M.J., Mart\u00ednez-Diez, M., Martinez-Leal, J.F., Akhmanova, A., and Aviles, P. (2018). Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4086-2"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Newman, D.J., and Cragg, G.M. (2017). Current status of marine-derived compounds as warheads in anti-tumor drug candidates. Mar. Drugs, 15.","DOI":"10.3390\/md15040099"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V124.21.4457.4457","article-title":"Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"124","author":"Morschhauser","year":"2014","journal-title":"Blood"},{"key":"ref_82","unstructured":"ClinicalTrials.gov (2019, March 29). Polatuzumab vedotin, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=polatuzumab+vedotin&cntry=&state=&city=&dist=&Search=Search."},{"key":"ref_83","unstructured":"European Union Clinical Trials Register (2019, March 29). Polatuzumab Vedotin. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr\u2013search\/search?query=polatuzumab+vedotin."},{"key":"ref_84","unstructured":"European Medicines Agency (2019, March 29). Polatuzumab vedotin. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Annex_to_CHMP_highlights\/2017\/06\/WC500230050.pdf."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2017.35.15_suppl.106","article-title":"A phase I study of enfortumab vedotin (ASG-22CE.; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer","volume":"35","author":"Petrylak","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2016.02.008","article-title":"New developments for antibody-drug conjugate-based therapeutic approaches","volume":"40","author":"Lambert","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"TPS1110","DOI":"10.1200\/jco.2015.33.15_suppl.tps1110","article-title":"METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)","volume":"33","author":"Yardley","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.05.010","article-title":"Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer","volume":"179","author":"Rose","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","article-title":"ABT-414, an antibody\u2013drug conjugate targeting a tumor-selective EGFR epitope","volume":"15","author":"Phillips","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1200\/jco.2015.33.15_suppl.2503","article-title":"Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC)","volume":"33","author":"Thompson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.2018.36.15_suppl.2023","article-title":"Updated results of the INTELLANCE 2\/EORTC trial 1410 randomized phase II study on Depatux-M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)","volume":"36","author":"French","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_94","unstructured":"AbbVie (2019, March 29). FDA rare pedriatic disease designation for investigational ABT\u2013414 for the treatment of a type of pediatric brain tumor known as Diffuse Intrinsic Pontine Glioma (DIPG). Available online: https:\/\/news.abbvie.com\/news\/abbvie\u2013receives\u2013us\u2013fda\u2013rare\u2013pediatric\u2013disease\u2013designation\u2013for\u2013investigational\u2013abt\u2013414\u2013for\u2013treatment\u2013type\u2013pediatric\u2013brain\u2013tumor\u2013known\u2013as\u2013diffuse\u2013intrinsic\u2013pontine\u2013glioma\u2013dipg.htm."},{"key":"ref_95","unstructured":"ClinicalTrials.gov (2019, March 29). Depatuxizumab mafodotin, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=depatuxizumab+mafodotin&cntry=&state=&city=&dist=&Search=Search."},{"key":"ref_96","unstructured":"European Union Clinical Trials Register (2019, March 29). Depatuxizumab Mafodotin. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr\u2013search\/search?query=depatuxizumab+mafodotin."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"10527","DOI":"10.1021\/jm501649k","article-title":"Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications","volume":"57","author":"Maderna","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1021\/jm990241l","article-title":"Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove","volume":"42","author":"Hurley","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","article-title":"Ecteinascidin\u2013743 (ET\u2013743), a natural marine compound, with a unique mechanism of action","volume":"37","author":"Erba","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1158\/0008-5472.CAN-06-0179","article-title":"Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin","volume":"66","author":"Herrero","year":"2006","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6925","DOI":"10.1021\/jm060640y","article-title":"Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA","volume":"49","author":"Marco","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/era.13.49","article-title":"13 Years of trabectedin, 5 years of Yondelis\u00ae: What have we learnt?","volume":"13","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/onc.2013.462","article-title":"Mode of action of trabectedin in myxoid liposarcomas","volume":"33","author":"Frapolli","year":"2014","journal-title":"Oncogene"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.ejca.2007.05.003","article-title":"Targeting DNA repair as a promising approach in cancer therapy","volume":"43","author":"Damia","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/BJ20101770","article-title":"Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906","volume":"437","author":"Soares","year":"2011","journal-title":"Biochem. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","article-title":"Role of homologous recombination in trabectedin-induced DNA damage","volume":"44","author":"Tavecchio","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.1221","article-title":"Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways","volume":"92","author":"Damia","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2011.01.016","article-title":"Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study","volume":"47","author":"Taron","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/ijc.28213","article-title":"Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis\u00ae (PM00104)","volume":"133","author":"Romano","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_112","first-page":"1327","article-title":"Overcoming multidrug resistance in P-glycoprotein\/MDR1-overexpressing cell lines by ecteinascidin 743","volume":"1","author":"Kanzaki","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/md12020719","article-title":"Trabectedin and plitidepsin: Drugs from the sea that strike the tumor microenvironment","volume":"12","author":"Galmarini","year":"2014","journal-title":"Mar. Drugs"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e24614","DOI":"10.4161\/onci.24614","article-title":"Trabectedin: A drug from the sea that strikes tumor-associated macrophages","volume":"2","author":"Allavena","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumor-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","article-title":"Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells","volume":"70","author":"Germano","year":"2010","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1124\/mol.106.026641","article-title":"Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin","volume":"70","author":"Dabydeen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial\u2013mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-824X-6-3","article-title":"Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro","volume":"6","author":"Agoulnik","year":"2014","journal-title":"Vasc. Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bcp.2014.01.026","article-title":"PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors","volume":"88","author":"Pera","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"13817","DOI":"10.1073\/pnas.1408124111","article-title":"A new tubulin\u2013binding site and pharmacophore for microtubule\u2013destabilizing anticancer drugs","volume":"111","author":"Prota","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1021\/ja058320b","article-title":"Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding","volume":"128","author":"Groll","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm048995+","article-title":"Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor","volume":"48","author":"Macherla","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.14113","article-title":"Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients","volume":"174","author":"Levin","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with\/without rituximab in patients with relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1535-7163.MCT-14-0798","article-title":"High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates","volume":"14","author":"Satijn","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1158\/1535-7163.MCT-13-0896","article-title":"SGN-LIV1A: A novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer","volume":"13","author":"Sussman","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: A new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1535-7163.MCT-15-0570","article-title":"Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new urothelial cancer biomarker","volume":"15","author":"Morrison","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.bmc.2008.10.075","article-title":"Discovery and development of the anticancer agent salinosporamide A (NPI-0052)","volume":"17","author":"Fenical","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1021\/ja962480t","article-title":"Enantioselective total synthesis of ecteinascidin 743","volume":"118","author":"Corey","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1021\/ol0062502","article-title":"Synthesis of ecteinascidin ET\u2013743 and phthalascidin Pt-650 from cyanosafracin B","volume":"2","author":"Cuevas","year":"2000","journal-title":"Org. Lett."}],"container-title":["Marine Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-3397\/17\/6\/329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:55:35Z","timestamp":1760187335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-3397\/17\/6\/329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,2]]},"references-count":140,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["md17060329"],"URL":"https:\/\/doi.org\/10.3390\/md17060329","relation":{},"ISSN":["1660-3397"],"issn-type":[{"value":"1660-3397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,2]]}}}